Vertex Pharmaceuticals Incorporated (VRTX) Holdings Increased by Schroder Investment Management Group

Schroder Investment Management Group grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,309 shares of the pharmaceutical company’s stock after buying an additional 1,849 shares during the period. Schroder Investment Management Group’s holdings in Vertex Pharmaceuticals were worth $4,031,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Renaissance Technologies LLC lifted its holdings in Vertex Pharmaceuticals by 42.1% during the 2nd quarter. Renaissance Technologies LLC now owns 4,050,617 shares of the pharmaceutical company’s stock worth $688,443,000 after buying an additional 1,199,700 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Vertex Pharmaceuticals by 4.1% during the 2nd quarter. Wells Fargo & Company MN now owns 2,087,508 shares of the pharmaceutical company’s stock worth $354,794,000 after buying an additional 82,811 shares during the last quarter. Fred Alger Management Inc. lifted its holdings in Vertex Pharmaceuticals by 10.8% during the 2nd quarter. Fred Alger Management Inc. now owns 1,960,493 shares of the pharmaceutical company’s stock worth $333,205,000 after buying an additional 191,072 shares during the last quarter. Putnam Investments LLC lifted its holdings in Vertex Pharmaceuticals by 2.3% during the 2nd quarter. Putnam Investments LLC now owns 1,751,760 shares of the pharmaceutical company’s stock worth $297,730,000 after buying an additional 39,166 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in Vertex Pharmaceuticals by 9.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,663,552 shares of the pharmaceutical company’s stock worth $282,738,000 after buying an additional 143,730 shares during the last quarter. 93.53% of the stock is owned by institutional investors.

Shares of VRTX stock opened at $175.69 on Friday. The stock has a market capitalization of $47.40 billion, a P/E ratio of 219.61, a P/E/G ratio of 1.87 and a beta of 1.48. Vertex Pharmaceuticals Incorporated has a 52-week low of $136.50 and a 52-week high of $194.92. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.55 and a current ratio of 3.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, July 25th. The pharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.40 by $0.54. The firm had revenue of $752.20 million for the quarter, compared to analysts’ expectations of $680.86 million. Vertex Pharmaceuticals had a return on equity of 19.86% and a net margin of 15.84%. The firm’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.39 EPS. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 2.51 EPS for the current fiscal year.

In related news, SVP Paul M. Silva sold 2,098 shares of the business’s stock in a transaction dated Friday, August 3rd. The stock was sold at an average price of $174.44, for a total value of $365,975.12. Following the transaction, the senior vice president now owns 17,376 shares in the company, valued at approximately $3,031,069.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Stuart A. Arbuckle sold 10,083 shares of the business’s stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $175.29, for a total value of $1,767,449.07. Following the completion of the transaction, the executive vice president now owns 48,877 shares in the company, valued at approximately $8,567,649.33. The disclosure for this sale can be found here. Insiders sold a total of 33,325 shares of company stock worth $6,135,340 in the last 90 days. 1.80% of the stock is currently owned by insiders.

Several research firms have recently weighed in on VRTX. Morgan Stanley boosted their target price on Vertex Pharmaceuticals from $207.00 to $211.00 and gave the company an “overweight” rating in a report on Thursday, July 26th. Zacks Investment Research downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, September 11th. Jefferies Financial Group boosted their target price on Vertex Pharmaceuticals to $210.00 and gave the company a “buy” rating in a report on Monday, July 16th. BidaskClub downgraded Vertex Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 20th. Finally, Royal Bank of Canada reissued a “buy” rating and issued a $203.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, July 26th. Four research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $197.68.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Read More: Understanding each part of a balance sheet

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply